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MicroRNAs (miRs) are one of the most important post-transcriptional repressors of
gene expression. However, miR-574-5p has recently been shown to positively regulate
the expression of microsomal prostaglandin E-synthase-1 (mPGES-1), a key enzyme
in the prostaglandin E2 (PGE2) biosynthesis, by acting as decoy to the RNA-binding
protein CUG-RNA binding protein 1 (CUGBP1) in human lung cancer. miR-574-5p
exhibits oncogenic properties and promotes lung tumor growth in vivo via induction
of mPGES-1-derived PGE2 synthesis. In a mass spectrometry-based proteomics study,
we now attempted to characterize this decoy mechanism in A549 lung cancer cells
at a cellular level. Besides the identification of novel CUGBP1 targets, we identified
that the interaction between miR-574-5p and CUGBP1 specifically regulates mPGES-1
expression. This is supported by the fact that CUGBP1 and miR-574-5p are located in
the nucleus, where CUGBP1 regulates alternative splicing. Further, in a bioinformatical
approach we showed that the decoy-dependent mPGES-1 splicing pattern is unique.
The specificity of miR-574-5p/CUGBP1 regulation on mPGES-1 expression supports
the therapeutic strategy of pharmacological inhibition of PGE2 formation, which may
provide significant therapeutic value for NSCLC patients with high miR-574-5p levels.
Keywords: miR-574-5p, CUGBP1, non-canonical miR function, decoy, proteomics, mPGES-1, lung cancer
Abbreviations: 1, knockdown; CUGBP1, CUG-RNA binding protein 1; FISH, fluorescence in situ hybridization; hnRNP
E2, Heterogenous Nuclear Ribonucleoprotein E2; IL, Interleukin; IPA, Ingenuity pathway analysis; miR, microRNA; mPGES-
1, microsomal prostaglandin E-synthase-1; NDUFS2, NADH- Ubiquinone Oxidoreductase Core Subunit S2; nt, nucleotides;
oe, overexpression; PGE2, prostaglandin E2; RBP, RNA-binding protein; RIP, RNA immunoprecipitation; SEM, standard
error of mean; SMAD, Mothers against decapentaplegic homolog; TMT, tandem mass tag; UTR, untranslated region.
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INTRODUCTION
MicroRNAs (miRs) represent a large family of small non-
coding RNAs of approximately 21 nucleotide length. MiRs
have proven to be important post-transcriptional regulators
of gene expression in eukaryotes (Jansson and Lund, 2012).
It is predicted that miRs control the expression of about
60% of human protein-coding genes (Friedman et al., 2009;
Schwanhäusser et al., 2011) and participate in the regulation
of almost all cellular processes. Importantly, they have emerged
as critical regulators of tumorigenesis and progression of
different types of cancer, since certain miRs can lead to a
dysregulation of processes like cell differentiation (Harfe, 2005),
cell cycle (Carleton et al., 2007), and apoptosis (Jovanovic
and Hengartner, 2006). Mechanistically, miRs are known to
repress expression of their target genes by base-pairing to 3′
untranslated regions (UTRs) (Wienholds and Plasterk, 2005).
Depending on the level of complementarity, miR binding
leads to either translational repression or degradation of the
mRNA. Both regulatory miR functions result in strongly
impaired gene expression and a decreased protein level
(Guo et al., 2010).
In contrast to this, over the last years different studies have
discovered new non-canonical miR functions. MiRs are not
only able to inhibit gene expression, but also to activate gene
expression. They can bind to RNA-binding proteins (RBPs)
and sequester them from their target mRNA. This function is
independent of the miR’s seed region and operates exclusively
by interference with a RBP. It was shown for the first time for
miR-328 which acts as RNA decoy for the heterogeneous nuclear
ribonucleoprotein E2 (hnRNP E2), a global gene expression
repressor (Eiring et al., 2010; Saul et al., 2016, 2019b).
Recently, a new miR/RBP interaction was discovered. MiR-
574-5p reveals a binding site for CUG-RNA binding protein 1
(CUGBP1) in its mature form (Saul et al., 2019a). Therefore,
it can directly interact with CUGBP1 and promotes lung
tumor growth in vivo by inducing microsomal prostaglandin
E-synthase-1 (mPGES-1) expression, the terminal synthase
responsible for the production of the pro-tumorigenic lipid
mediator prostaglandin E2 (PGE2) (Nakanishi and Rosenberg,
2013). In human lung tumor and under inflammatory
circumstances, miR-574-5p is strongly upregulated and increases
mPGES-1 expression by preventing CUGBP1 binding to the
mPGES-1 3′UTR which leads to an enhanced alternative
splicing and the generation of a novel 3′UTR isoform (Saul
et al., 2019a). The newly discovered link between miR-574-5p
overexpression and PGE2-mediated tumor growth in vivo
suggests that pharmacological inhibition of PGE2 formation
might be a potential therapeutic approach in combination with
standard therapies for lung cancer patients with high miR-574-5p
levels (Saul et al., 2019a). Thereby, miR-574-5p could serve as a
stratification and biomarker to identify suitable candidates, an
approach which is also supported by earlier studies (Foss et al.,
2011; Del Vescovo et al., 2014).
To identify new CUGBP1 targets and characterize the global
impact of the novel RNA decoy mechanism of miR-574-5p
and CUGBP1, with the aim of demonstrating the specificity
of the biomarker miR-574-5p, we applied a tandem mass
tag (TMT)-based proteomics approach in A549 lung cancer
cells. In this study, we were able to identify and validate
novel CUGBP1 targets like Mothers against decapentaplegic
homolog (SMAD) 2 which is an important signal transducer
and transcription factor. Moreover, we demonstrate that the
miR-574-5p/CUGBP1 decoy mechanism could be specific for
mPGES-1 in human lung cancer due to a very unique splicing
pattern in the 3′UTR of mPGES-1.
MATERIALS AND METHODS
Cell Line and Cell Culture Conditions
The human lung adenocarcinoma cell line A549 (ATCC) was
cultured in Dulbecco’s modified Eagle medium (DMEM, Life
Technologies, Thermo Fisher Scientific) with 10% (v/v) fetal
bovine serum (FBS, Life Technologies, Thermo Fisher Scientific),
100 U/ml penicillin, 100 µg/ml streptomycin and 1 mM sodium
pyruvate (PAA the Cell Culture Company). Cell culture was
carried out in a humidified atmosphere of 5% CO2 at 37◦C.
RNA Interference
A549 cells were seeded at a density of 5 × 105 cells/well in a
6-well plate and treated with 20 pmol siRNA oligonucleotides
the next day using Lipofectamine 2000 R© (Invitrogen) according
to manufacturer’s instructions. A previously published anti-
CUGBP1 siRNA (5′-GCUGUUUAUUGGUAUGAUU-3′) was
used for transient knockdown (1) of CUGBP1 (Vlasova-St Louis
and Bohjanen, 2011). As control, a scramble siRNA with an
unspecific sequence (5′-UCUCUCACAACGGGCAUUU-3′) was
used. 24 h after transfection, A549 cells were incubated with
5 ng/ml of Interleukin (IL)-1β (Sigma-Aldrich) for further 24 h.
The efficiency of the knockdown was determined by Western blot
analysis as described in Saul et al. (2019a).
Transfection of miR-574-5p Mimic or
Inhibitor (miR Overexpression or miR
Knockdown)
A549 cells were seeded at a density of 5× 105 per well in a 6-well
plate. For overexpression of miR-574-5p, 100 pmol miRIDIAN
miR-574-5p mimics (HMI0794, Sigma-Aldrich) or negative
control mimic (HMC0002, Sigma-Aldrich) were transfected
using Lipofectamine 2000 R© according to the manufacturer’s
instructions. In the same way, the A549 cells were transfected
with 200 pmol miR-574-5p-LNATM inhibitor (4101451-001,
Exiqon) or negative control LNA (199006-001, Exiqon) for the
knockdown of miR-574-5p. 24 h after transfection, A549 cells
were incubated with 5 ng/ml of IL-1β (Sigma-Aldrich) for further
24 h. The transfection efficiency was determined by qRT-PCR.
Fraction Preparation
In order to find compartment specific regulations, soluble and
microsomal proteins of A549 cells were separately analyzed.
The fractionation was performed as previously described (Saul
et al., 2016). Protein content of Western blot samples was
Frontiers in Pharmacology | www.frontiersin.org 2 March 2020 | Volume 11 | Article 196
fphar-11-00196 March 12, 2020 Time: 14:34 # 3
Emmerich et al. CUGBP1/miR-574-5p Decoy in Lung Cancer
determined by Bradford assay (Bio-Rad Laboratories), for
proteomics samples the protein amount was determined by
Pierce BCA Protein Assay (Thermo Fisher Scientific) following
manufacturing instructions.
Trypsin Digestion, TMT Labeling and
Peptide Fractionation
The protein pellets were solubilized in 50 µl buffer containing
0.05 M triethylammonium bicarbonate, 4 M urea, 0.01% SDS and
2% RapiGest SF Surfactant (Waters). Equal protein amount from
each sample (50 µg) was taken as starting point for further sample
preparation. Disulfide reduction was performed by adding 5 µl
1 M DTT (in H2O) for 30 min at 56◦C followed by sulfhydryl
alkylation performed by adding 4 µl iodoacetamide solution (1
M in H2O) and incubation at RT for 1 h in the dark. Trypsin
(modified sequencing grade, Promega) was added in a ratio
of 1:30 (trypsin: protein) and the samples were incubated at
37◦C overnight. Peptide labeling was performed using tandem
mass tags (TMT 6-plex, Thermo Fisher Scientific) according to
the instructions of the manufacturer (Table 1). Labeled peptide
samples were pooled to final soluble and microsomal fractions
and excess reagents were removed by solid phase extraction
(STRATA XC Phenomenex). Liquid chromatography tandem MS
of a TMT-labeled sample was performed on QExactive mass
spectrometer (Thermo Fisher Scientific).
Peptide pre-fractionation was done essentially as described
(Cao et al., 2012). Briefly, TMT-labeled protein digests were
separated over a 60 min gradient (3–55% B-buffer) on a
2.1 × 250 mm XBridge BEH300 C18 column (Waters) using a
flow rate of 200 µL/min. A- and B-buffers consisted of 20 mM
ammonia in MilliQ-grade water or 20 mM ammonia in 80%
acetonitrile, respectively. Individual fractions were collected per
minute and the fractions covering the peptide elution range were
concatenated to yield 12 final pooled fractions. These fractions
were evaporated to dryness by vaccume drying and stored frozen
until nanoLC-MS data capture.
Mass Spectrometry
Online LC-MS was performed using a Q-Exactive mass
spectrometer (Thermo Scientific). Peptide samples were trapped
on an Acclaim PepMap trap column (C18, 3 µm, 100Å,
75 µm × 20 mm), and separated on a 15-cm long C18
picofrit column (100 µm internal diameter, 5 µm bead size,
Nikkyo Technos, Tokyo, Japan) installed on to the nano-
electrospray ionization source. Solvent A was 97% water, 3%
acetonitrile, 0.1% formic acid; and solvent B was 5% water,
95% acetonitrile, 0.1% formic acid. At a constant flow of
0.25 µl/min, the curved gradient went from 3% B up to
48% B in 50 min.
FTMS master scans with 70,000 resolution (and mass range
400–1200 m/z) were followed by data-dependent MS/MS (17,500
resolution) on the top 10 precursor ions using higher energy
collision dissociation (HCD) at 31% normalized collision energy.
Precursors were isolated with a 2 m/z window. Automatic gain
control (AGC) targets were 3e6 for MS1 and 2e5 for MS2.
Maximum injection times were 250 ms for MS1 and 200 ms for
MS2. Dynamic exclusion was used with 20 s duration. Precursors
with unassigned charge state or charge state 1 were excluded. An
underfill ratio of 1% was used. The mass spectrometry proteomics
data have been deposited to the ProteomeXchange Consortium
via the PRIDE (Perez-Riverol et al., 2019) partner repository with
the dataset identifier PXD016803.
Data Analysis
Acquired MS raw files were searched using Sequest-Percolator
under the software platform Proteome Discoverer 1.4.1.14
(Thermo Fisher Scientific) against human Uniprot database
(release 01.12.2015) and filtered to a 1% FDR cut off. We used
a precursor ion mass tolerance of 10 ppm, and product ion
mass tolerances of 0.02 Da for HCD-FTMS. The algorithm
considered tryptic peptides with maximum 2 missed cleavages;
carbamidomethylation (C), TMT 6-plex (K, N-term) as fixed
modifications and oxidation (M) as dynamic modifications.
Quantification of reporter ions was done by Proteome Discoverer
on HCD-FTMS tandem mass spectra using an integration
window tolerance of 10 ppm. Only unique peptides in the
data set were used for quantification. Fold values were
calculated comparing proteins from 1CUGBP1 to Scramble,
1miR-574-5p to negative control LNA and miR-574-5p oe
to negative control mimic. Fold values of +1.5/−1.5 were
considered up-/downregulated. All regulated proteins in soluble
as well as microsomal fractions from all three conditions were
analyzed using Ingenuity Pathway Analysis (IPA) (Ingenuity
Systems1). We predicted the five most affected canonical
pathways. The canonical pathways with p-values ≤ 0.05 were
defined as significant.
RNA Extraction
Total RNA was extracted with TRIzol reagent (Invitrogen)
and treated with Turbo DNase (Ambion, Thermo Fisher
Scientific) according to manufacturer’s instructions. RNA
concentration was determined with NanoDrop (Peqlab). DNase-
treated RNA was used for reverse transcription. For mRNAs,
the High-Capacity cDNA reverse transcription Kit (Applied
Biosystems, Thermo Fisher Scientific) was used according
to manufacturer’s instructions. For miR detection, RNA was
transcribed with the miScript II RT Kit (Qiagen) according to
manufacturer’s instructions.
Quantitative Reverse Transcription PCR
(qRT-PCR)
qRT-PCR was performed with Applied Biosystems StepOne
PlusTM Real-Time PCR System (Applied Biosystem, Thermo
Fisher Scientific). 1 µl cDNA (1:2 diluted) was used per reaction.
For mRNA quantification, qRT-PCR was performed using Fast
SYBR Green PCR Master Mix (Applied Biosystems, Thermo
Fisher Scientific). The sequences for primer pairs are listed in
Table 2. qRT-PCR based miR quantification was performed using
miScript system (Qiagen). It was performed using the miR-
574-5p specific primer (MS00043617, Qiagen). qRT-PCR was
1www.ingenuity.com
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performed according to the manufacturer’s instructions. Fold
inductions were calculated using 2(−1Ct) value.
RNA Immunoprecipitation (RIP)
RNA immunoprecipitation was performed as previously
described (Saul et al., 2019a). In short, 6 × 106 A549 cells per
RIP were resuspended in lysis buffer containing 10 mM Tris-HCl
(Carl Roth) pH 7.5, 10 mM KCl (Sigma-Aldrich), 1.5 mM MgCl2,
0.5 mM DTT (Sigma-Aldrich), 0.9% Nonidet P-40 (Sigma-
Aldrich), 20 µl ribonuclease inhibitor and protease inhibitor
EDTA-free (Roche). The suspension was sonicated. Afterward,
samples were centrifuged, supernatant was transferred into a
fresh tube and 10% were taken as input sample. We used blocked
GammaBind Plus Sepharose beads (GE Healthcare). Beads and
antibodies were linked by mixing 50 µl bead suspension with
10 µg of CUGBP1 antibody (05-621 clone3B1, Merck) or normal
mouse IgG antibody (12-371, Merck). The IP was then conducted
by dividing the lysate equally to the CUGBP1-/IgG-bead mixture
and incubating for 2 h at 4◦C. Afterward, samples were washed
and 10% of each precipitate was taken for Western blot analysis
to validate the IP. The remaining precipitates were resuspended
in 500 µl TRIzol reagent (Invitrogen) and RNA was isolated
as described above. Subsequent qRT-PCR based mRNA or
miR quantification was performed as previously described. All
buffers and solutions contained protease inhibitor EDTA-free
(Roche). Successful precipitation was verified via Western blot
analysis with a primary antibody directed against CUGBP1
(ab129115, Abcam).
Western Blotting
Western blot analysis was performed as previously described
(Ochs et al., 2013). Briefly, the Odyssey Imaging System (Li-COR
Biosciences) was used which allows a linear quantification using
near-infrared fluorescence. The membranes were incubated
with primary antibodies that recognize CUGBP1 (ab9549,
Abcam), SMAD2 (sc-6200, Santa Cruz), SMAD3 (ab28379,
Abcam), SMAD4 (ab3219, Abcam), p38 (sc-535, Santa Cruz),
NDUFS2 (ab96160, Abcam), mPGES-1 [160140, Cayman-
Chemical (Westman et al., 2004)], β-Actin (sc-1616, Santa Cruz).
Bioinformatical 3′UTR Analysis
For the analysis of splice patterns, we concentrated on the list
of proteins that were upregulated at least 1.5-fold in response to
1CUGBP1 concerning the mass spectrometry data. All described
3′UTR sequences of those 399 proteins were downloaded from
ensemble biomart [GRCh38/.p12, version 91, Ensembl variation
resources (Hunt et al., 2018)], resulting in a list of 1916
transcripts. Those were aligned with 42 different binding motifs
of CUGBP1 that were known so far [downloaded from the online
tool Splice Aid F (Marquis et al., 2006; Giulietti et al., 2013)].
Then, three criteria were applied (high stringency analysis):
(I) binding sites should be of 39 or 46 nucleotides (nt) length,
(II) there should be 2 binding sites and (III) those binding sites
should span a potential intron of 1000 nt. For a second less
stringent approach (referred to as low stringency analysis), we
investigated transcripts (I) with binding sites of at least 8 nt length
(II), at least 2 binding sites and (III) those binding sites should
span a potential intron of 100 nt. Analysis was conducted using
Microsoft Excel.
Immunofluorescence
Immunofluorescent staining was performed as previously
described (Saul et al., 2019a). A549 cells were seeded on glass
cover slips (12 mm, Neolab) at a density of 2.5 × 105 per well
in a 6-well plate and incubated for 24 h. Cells were washed with
PBS, prior to fixation with 4% formaldehyde (FA, Carl Roth)
for 10 min. After washing with PBS 3 times for 3 min, cells
were permeabilized with 0.5% Triton X-100 (Sigma-Aldrich) in
PBS for 10 min. Then, cells were blocked with 2% BSA (Sigma-
Aldrich) in PBS for 20 min. The primary antibody directed
against CUGBP1 (ab9549, Abcam) was diluted in blocking
solution (1:500) and incubated for 1 h at room temperature
together with fixed cells. Afterward, cells were washed 3 times
with 0.01% Tween20 (Carl Roth) in PBS for 5 min and incubated
for 45 min at room temperature with the secondary antibody goat
anti-mouse IgG (Alexa Fluor R© 594, ab150116, Abcam) diluted
in blocking solution (1:500). Finally, cells were washed with
0.01% Tween20 (Carl Roth) in PBS as described, counterstained
for 5 min with 4′,6-diamidine-2′-phenylindole dihydrochloride
(DAPI, Sigma-Aldrich) and mounted in Mowiol 4-88 mounting
medium (Sigma-Aldrich).
Fluorescent In situ Hybridization (FISH)
FISH was performed as previously described (Saul et al., 2019a).
2.5 × 105 A549 cells were seeded on glass cover slips (12 mm,
Neolab) in 6-well plates and incubated for 24 h. Cells were washed
with PBS and prefixed with 1% FA in PBS for 10 min. After 3
washing steps of 3 min with PBS, cells were permeabilized with
0.5% Triton X-100 in PBS for 20 min on ice. After additional
three washing steps of 3 min with PBS, cells were refixed with
4% FA for 10 min followed by further washing with PBS 3 times
for 3 min. Subsequently, samples were prehybridized for 30 min
at 40◦C in microRNA ISH buffer (Qiagen) and then hybridized
for 1 h at 54◦C with 100 nM double digoxigenin (DIG) labeled
miR-574-5p probe (Qiagen) diluted in microRNA ISH buffer.
After hybridization, samples were washed twice for 5 min with 2x
saline-sodium citrate buffer (Gibco, Carlsbad, CA, United States)
at hybridization temperature and once at room temperature
followed by a 20 min blocking step with 2% BSA in PBS.
Subsequently, cells were incubated for 1 h at room temperature
with rabbit anti-DIG antibody (9H27L19, Invitrogen, Thermo
Fisher Scientific) diluted 1:40 in blocking solution. Afterward,
cells were washed with 0.01% Tween20 in PBS 3 times for
5 min and incubated at room temperature for 45 min with
secondary antibody goat anti-rabbit IgG (Alexa Fluor R© 594, 111-
585-144, Jackson ImmunoResearch) diluted 1:300 in blocking
solution. Then, cells were washed with 0.01% Tween20 in PBS,
counterstained with DAPI and mounted as described.
Microscopy
The Leica TCS SPE confocal point scanner mounted on a Leica
DMi8 stand equipped with an oil immersion 63 × Apochromat
was used in order to take confocal images of immunofluorescence
and miR FISH samples. For all samples, the 405 and 561 nm
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laser lines were used to perform excitation. All images were
analyzed using the ImageJ software and show one focal plane of
the middle of the nucleus.
Statistics
Results are shown as mean + Standard error of mean (SEM)
of at least three independent experiments. Statistical analysis
was carried out by Student’s paired or unpaired t-test (two-
tailed) using GraphPad Prism 5.0. Differences were considered
as significant for p ≤ 0.05 (indicated as ∗ for p ≤ 0.05, ∗∗ for
p ≤ 0.005, and ∗∗∗ for p ≤ 0.001).
RESULTS
Analysis of Protein Expression Changes
in Response to 1CUGBP1, 1miR-574-5p,
and miR-574-5p oe in IL-1β-Stimulated
A549 Cells
A stable isotope labeling based proteomics study was
conducted to identify changes in the proteome of A549 lung
cancer cells stimulated with IL-1β (Figure 1). A549 cells with
1CUGBP1, 1miR-574-5p or miR-574-5p oe were compared
to their corresponding controls. Knockdown of CUGBP1 was
validated via Western blot analysis and showed a reduction of
67% in the soluble fraction and 83% in the microsomal fraction
of A549 cells (Supplementary Figure S1). Knockdown and
overexpression of miR-574-5p were quantified with qRT-PCR
analysis and revealed a significant∼80% decrease of miR-574-5p,
FIGURE 1 | Proteomics study workflow. A549 cells with 1CUGBP1,
1miR-574-5p, or miR-574-5p oe and respective controls. Soluble and
microsomal proteins were isolated, trypsin digested and TMT-labeled.
Afterward, the LC-MS/MS measurement was conducted, the data were
analyzed and the pathway analysis was performed. 1, knockdown; oe,
overexpression; TMT, tandem mass tag.
while miR-574-5p was ∼300-fold upregulated in the miR-574-
5p oe samples (Supplementary Figure S1). For the LC-MS/MS
analysis, all samples were digested and were labeled with TMT
6-plex to allow quantitative protein comparison (Table 1). In
all three conditions (1CUGBP1, 1miR-574-5p or miR-574-5p
oe) we identified roughly the same numbers of total protein (in
soluble fraction around 2450 and in microsomal fraction around
3970 proteins). But only small percentages of them revealed an
up- or downregulation in comparison to their corresponding
controls (Figure 2). Overall, we set the criteria for upregulation
to a TMT ratio of ≥1.5 (fold change ≥ 1.5) and downregulation
was considered with a TMT ratio of ≤0.5 (fold change ≤ −1.5).
In 1CUGBP1 cells, canonical targets of CUGBP1 as well as
decoy targets were supposed to show an upregulation in response
to the knockdown. In the soluble fraction, 2% were indeed
upregulated (61 proteins) and 8% (187 proteins) of all detected
proteins were downregulated. In the microsomal fraction, 9%
(338 proteins) were elevated, while 4% (152 proteins) showed
a downregulation. In miR-574-5p oe cells, we expected direct
miR targets to be decreased and decoy targets to be increased in
response to high miR-574-5p levels. In the soluble fraction, 2%
(40 proteins) were up- and 3% (78 proteins) were downregulated.
While a decrease was measured for 8% of microsomal proteins
(303 proteins), only 3% were upregulated (124 proteins). In the
soluble fraction, 1% (29 proteins) of the total protein amount
was decreased upon 1miR-574-5p, while 14 proteins showed
an increase. However, the microsomal proteins showed higher
percentages, 9% were upregulated (345 proteins), while even 13%
(504 proteins) showed a downregulation.
Overall, the results show that on average 11% of all analyzed
proteins are regulated by CUGBP1, while 9.7% of all detected
proteins show an expression change related to miR-574-5p. But
the distribution of the miR-574-5p regulated proteins varies
considerably depending on the protein fraction.
IPA Predicts Top Canonical Pathways
and Upstream Regulators
Next, we analyzed all regulated proteins in soluble as well as
microsomal fraction using IPA (Ingenuity Systems). The most
TABLE 1 | TMT labeling of protein samples in the proteomics study.
Sample name Fraction Label reagent
Control 1CUGBP1 (Scramble) Soluble 126
1CUGBP1 Soluble 127
Control miR-574-5p oe Soluble 128
miR-574-5p oe Soluble 129
Control 1miR-574-5p Soluble 130
1miR-574-5p Soluble 131
Control 1CUGBP1 (Scramble) Microsomal 126
1CUGBP1 Microsomal 127
Control miR-574-5p oe Microsomal 128
miR-574-5p oe Microsomal 129
Control 1miR-574-5p Microsomal 130
1miR-574-5p Microsomal 131
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FIGURE 2 | Numbers of regulated proteins. Numbers of differentially expressed proteins upon 1CUGBP1, 1miR-574-5p, or miR-574-5p oe in soluble and
microsomal fraction of the proteomics study. Cut-offs were set to 1.5-fold for upregulation and -1.5-fold for downregulation. CUGBP1 binding sites of upregulated
proteins were predicted using splice aid www.introni.it/spliceaid.html, while miR-574-5p seed regions were identified with the online tool microrna.org. of proteins
revealing an upregulation upon 1miR-574-5p or a downregulation upon miR-574-5p oe. 1, knockdown; oe, overexpression.
affected canonical pathways as well as upstream regulators were
predicted. Canonical pathways with p-values≤ 0.05 were termed
as significant. The analysis revealed that the Eukaryotic Initiation
Factor 2 (eIF2) Signaling, Regulation of Eukaryotic Initiation
Factor 4 (eIF4) and 70 kDa ribosomal S6 kinase (p70S6K)
Signaling, tRNA Charging, Protein Ubiquitination Pathway
and mechanistic Target of Rapamycin (mTOR) Signaling are
the most affected canonical pathways in the soluble fraction
(Supplementary Table S4). In the microsomal fraction, top
regulated pathways were eIF2 Signaling, Protein Ubiquitination
Pathway, Mitochondrial Dysfunction, Regulation of eIF4 and
p70S6K Signaling as well as Oxidative Phosphorylation. Top
predicted upstream regulators were Hepatocyte Nuclear Factor
4 Alpha (HNF4A), Cystatin D (CST5), Rapamycin-Insensitive
Companion of mTOR (RICTOR), MYC Proto-Oncogene,
MYCN Proto-Oncogene, microtubule associated protein tau
(MAPT) and Tumor Protein P53 (TP53) (Supplementary
Table S3), which further underlines the cancer context of
CUGBP1 and miR-574-5p.
Validation of TMT Based Quantification
of Proteomics Results Using Western
Blot Analysis
In order to validate the results of the proteomics study
(Supplementary Tables S1, S2), distinct proteins were selected to
be confirmed via Western blot analysis. Since this was a complex
study with many different conditions (Figure 1), we concentrated
not necessarily on physiologically connected proteins. We firstly
selected NADH-Ubiquinone Oxidoreductase Core Subunit S2
(NDUFS2) which is a postulated CUGBP1 target in HeLa cells
(Rattenbacher et al., 2010). Although there were no strong
changes of microsomal NDUFS2 in the proteomics study, soluble
NDUFS2 showed a trend toward slight upregulation in response
to 1CUGBP1 and miR-574-5p oe. This upregulation and also
the values for the microsomal fraction could be confirmed using
Western blot analysis (Supplementary Figure S2A, right panel).
In response to 1miR-574-5p, soluble NDUFS2 revealed a slight
decrease in the proteomics data which was also confirmed by
Western blot analysis (Supplementary Figure S2A, left panel).
In addition to this, SMAD3 was another target which we
aimed to validate. It was strongly downregulated in response
to 1CUGBP1 in the soluble fraction of the proteomics study
and we were also able to confirm this via Western blot
(Supplementary Figure S2B, left panel). While the proteomics
study revealed no strong regulation of SMAD3 in microsomal
fraction, IPA predicted it to be activated upon 1CUGBP1
(Supplementary Table S3). Indeed, we observed an upregulation
of SMAD3 proteins in the microsomal fraction performing
Western blot analysis (Supplementary Figure S2B, right panel).
In this case, we could validate the pathway analysis which is
based on the proteomics data (Supplementary Tables S1, S2).
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In response to 1miR-574-5p, SMAD3 was slightly upregulated
in the microsomal fraction which was also a tendency in the
proteomics study, although weaker. In general, the Western blot
data of the two miR-574-5p conditions showed higher variations
in SMAD3 levels.
SMAD2, another member of the same protein family, was
also predicted in the IPA to be upregulated upon 1CUGBP1
(Supplementary Table S3). Indeed, we were able to confirm this
regulation by Western blot analysis. We observed a significant
fourfold upregulation of SMAD2 in the microsomal fraction
(Supplementary Figure S2C, right panel). Interestingly, in the
soluble fraction SMAD2 expression was significantly reduced
(Supplementary Figure S2C, left panel) which indicates that
its regulation might be highly compartment specific. In soluble
and microsomal fraction, SMAD2 and SMAD3 revealed a
slight downregulation in response to miR-574-5p oe and an
upregulation in response to 1miR-574-5p in the microsomal
fraction. This indicated that both genes might be canonical miR-
574-5p targets. Therefore, we analyzed the 3′UTRs of SMAD2
and SMAD3 using the online tool microrna.org (Betel et al., 2010)
but found that none of them contains a seed region of miR-574-
5p. This suggests that the effects on protein level are caused by
secondary effects.
To complete the family of SMADs, it was coherent to analyze
SMAD4, as the only other SMAD that was detected in the
proteomics study. However, neither in the proteomics study nor
in the Western Blot images, it did depict any regulation upon
1CUGBP1 (Supplementary Figure S3A) which validated the
mass spectrometry data, but excluded SMAD4 as interesting
potential target.
Finally, we studied p38 (MAPK14) which was one of the
strongest downregulated proteins upon 1CUGBP1 in the soluble
fraction of the proteomics study. In fact, we verified this
severe decrease of p38 protein using Western blot analysis
(Supplementary Figure S3B). Nevertheless, this effect seems to
be secondary, as CUGBP1 targets are supposed to be upregulated
in response to the knockdown.
Overall, these results validated the proteomics data
(Supplementary Tables S1, S2). Since we measured an increase
in NDUFS2, SMAD2 and SMAD3 as a response to 1CUGBP1,
we considered them as potential novel CUGBP1 targets.
Identification of New CUGBP1 Targets
Next, we aimed to identify new targets of the decoy mechanism,
but also CUGBP1 targets using bioinformatical approaches.
Therefore, we analyzed proteins which were increased upon
1CUGBP1 and analyzed their 3′UTRs for CUGBP1 binding sites.
We downloaded the 3′UTR sequences of the specific proteins
from the database UCSC Genome Browser (December 2013
GRCh38/hg38)2 (Kent et al., 2002) and analyzed them by using
the online tool SpliceAid 2 (Piva et al., 2009) to identify potential
CUGBP1 binding motifs. Thereby, the algorithm detects GU-rich
elements (GREs) and other binding motives (e.g., CUGUCUG)
in the provided 3′UTR sequences. In fact, a high number of
the upregulated proteins does have a potential CUGBP1 binding
2https://genome.ucsc.edu/
site: in the soluble fraction 69% (42 proteins) and in the
microsomal fraction 73% (246 proteins) of all detected proteins
in the proteomics study (Figure 2).
Since CUGBP1 itself was mainly detectable in the microsomal
fraction (Supplementary Figure S1A), we focused on this
fraction for further analysis. As a positive control we used
mPGES-1 which is already described as CUGBP1 target and
decoy target (Saul et al., 2019a). The three candidates SMAD2,
SMAD3 and NDUFS2 all depicted an upregulation in response to
1CUGBP1 visualized by Western blot analysis (Figures 3A,C,D)
and indeed also contained binding sites for CUGBP1 in their
3′UTRs. SMAD2 and SMAD3 both exhibit multiple binding
motifs all over their 3′UTRs, while NDUFS2 with a rather short
3′UTR, harbors only one binding site.
We also observed an increase on protein level of mPGES-
1 upon 1CUGBP1 which further supports our results from
the mass spectrometry (Figure 3B). This data provides first
evidence that SMAD2, SMAD3 and NDUFS2 could be CUGBP1
targets in A549 cells.
RIP Confirmed Binding of CUGBP1 to
mRNAs of Novel Targets
In order to further validate the new postulated targets
SMAD2, SMAD3, NDUFS2 as well as mPGES-1, binding of
CUGBP1 needed to be confirmed. Therefore, we performed
immunoprecipitation of CUGBP1 with a specific antibody and
then quantified the bound mRNAs via qRT-PCR. As mock
control we used a normal mouse IgG antibody. Binding was
assumed, if the specific mRNA showed an enrichment in
CUGBP1-IP, compared to IgG-IP. Successful RIP was verified
using Jun Proto-Oncogene AP-1 Transcription Factor Subunit
(cJUN) as positive control (Figure 3E) which revealed a
significant 2.4-fold enrichment. Cyclooxygenase (COX)-2 was
used as negative control, since it has no binding site and
was not influenced by CUGBP1 (Saul et al., 2019a). Indeed,
we could show that CUGBP1 binds to three of the mRNAs
(Figure 3F): SMAD2 mRNA was significantly 6.4-fold enriched.
NDUFS2 showed a 2.2-fold enrichment and mPGES-1 was 4.3-
fold enriched in comparison to IgG control. However, SMAD3
was not bound by CUGBP1 and showed no enrichment of
the mRNA although it contains a binding site in the 3′UTR.
Interestingly, it was also revealed that CUGBP1 binds its own
mRNA, as it showed a slight enrichment compared to IgG,
indicating an autoregulatory mechanism.
Overall, we confirmed CUGBP1 binding to three of the
four postulated targets: SMAD2, NDUFS2 and mPGES-1. Since
we assumed decoy targets to be a subpopulation of CUGBP1
targets, we aimed to investigate if these new candidates were also
regulated by miR-574-5p.
Identification of Novel
miR-574-5p/CUGBP1 Decoy Targets by
Investigating a “Decoy Regulation
Pattern” on Protein Level
In order to find new targets of the miR-574-5p/CUGBP1 decoy
mechanism, we analyzed the proteomics data in regard to a
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FIGURE 3 | Identification of novel CUGBP1 targets. Western blots of IL-1β-stimulated A549 cells with 1CUGBP1 showed increased levels of (A) NDUFS2, (B)
mPGES-1, (C) SMAD2 and (D) SMAD3 compared to control. β-Actin was used as loading control. Fold induction is given as mean (+SEM) of three independent
experiments, t-test ***p ≤ 0.001. (E,F) RIP with antibodies against CUGBP1 or IgG (mock) showed enrichment of bound mRNAs quantified via q RT-PCR. (E) cJUN
was used as positive control, COX-2 as negative control. (F) mRNAs of NDUFS2, mPGES-1, SMAD2 and CUGBP1 were enriched in CUGBP1-IP, while SMAD3
mRNA showed no enrichment. Relative enrichment normalized to IgG is given as mean (+SEM) from three independent experiments. t-test *p ≤ 0.05; **p ≤ 0.005.
RIP: RNA immunoprecipitation.
“decoy regulation pattern” in the three conditions (1CUGBP1,
1miR-574-5p or miR-574-5p oe) and aimed to verify it via
Western blot analysis. As subpopulation of CUGBP1 targets,
decoy targets should be increased in response to 1CUGBP.
Further, they are supposed to be downregulated upon 1miR-
574-5p, because lower miR levels cause higher binding capacity
of CUGBP1 which in turn has a negative effect on the
protein level. Vice versa, miR-574-5p oe should lead to an
upregulation of potential decoy targets, as more miRs are
available to prevent binding of CUGBP1. Here, we also included
those proteins showing a tendency for the “decoy regulation
pattern,” such as only two conditions that met the criteria
or only slight up- or downregulations, for instance NDUFS2
showed only a −1.33-fold induction in response to 1CUGBP1.
Another example is High-mobility group AT-hook 2 (HMGA2)
protein which was strongly upregulated upon 1CUGBP1 and
downregulated upon 1miR-574-5p but showed only a 1.14-fold
TMT ratio in response to miR-574-5p oe. As mentioned above,
we focused only on the microsomal fraction, since CUGBP1
was predominantly expressed there (Supplementary Figure S1).
We analyzed the newly postulated CUGBP1 target proteins and
several other candidates via Western blot. Although the control
decoy target mPGES-1 could be successfully validated, none
of the other potential candidates could be confirmed revealing
the “decoy regulation pattern” in the Western blot images.
Neither SMAD2, SMAD3 nor NDUFS2 showed the adequate
“decoy regulation pattern” concerning the two miR conditions
(Supplementary Figure S2). Other candidates such as glyoxalase
domain-containing protein 4 (GLOD4) or HMGA2 which were
detected by mass spectrometry, could not be validated herein.
Probably, the sensitivity of the Western blot system was too
low and the proteins were only expressed on a very basal
level by the cells.
We next analyzed the proteomics data again using more
stringent criteria. Taking a closer look how many proteins showed
a strong upregulation of ≥1.5-fold in response to 1CUGBP1
and a downregulation of ≤−1.5-fold after 1miR-574-5p and
at least an upregulation of ≥1.5-fold in response to miR-
574-5p oe. With these criteria set, zero proteins were found
in the soluble fraction (Figure 4A), while in the microsomal
fraction only seven proteins (0.2%) matched this regulation
pattern in all three conditions (Figure 4B). This gave us the
first hint that the CUGBP1/miR-574-5p decoy seems to be
a very specific mechanism, considering that originally around
3970 proteins were detected in the microsomal fraction in
the proteomics study. Those seven proteins were: Ubiquitin
Conjugating Enzyme E2 R2 (UBE2R2), Centrosomal Protein
of 41 kDa (CEP41), RNA polymerase-associated protein LEO1
(LEO1), General Transcription Factor IIE Subunit 2 (GTF2E2),
Polyadenylate-Binding Protein-Interacting Protein 2 (PAIP2),
Solute carrier family 39 member 6 (SLC39A6), GRIP1 Associated
Protein 1 (GRIPAP1). Of note, mPGES-1 was not among the
seven proteins, since it did not reveal the exact pattern in the
proteomics data either, probably due to the limitations of the
mass spectrometry procedure. While GRIPAP1 has no described
3′UTR, the other 3′UTRs were analyzed concerning CUGBP1
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FIGURE 4 | RIP excludes seven potential decoy candidates. Stringent criteria applied to results of the proteomics study: number of proteins which reveal an
upregulation (↑) upon 1CUGBP1, an upregulation upon miR-574-5p oe and a downregulation (↓) upon 1miR-574-5p in (A) soluble fraction and (B) microsomal
fraction. (C) In RIP assays of A549 cells, none of the mRNAs was enriched in CUGBP1-IP samples compared to IgG. Relative enrichment normalized to IgG is given
as mean (+SEM) from three independent experiments. 1, knockdown; oe, overexpression; RIP, RNA immunoprecipitation.
binding motifs and it was revealed that all of them did contain
a binding site in their 3′UTRs. By conducting a RIP binding
assay, we analyzed whether the potential decoy candidates were
bound by CUGBP1. It turned out that none of these six remaining
mRNAs showed an enrichment in the CUGBP1-IP compared
to mock control (Figure 4C). They were excluded as decoy
targets in A549 cells, since none of the candidates was bound
by CUGBP1. Thus, based on our Western blot and RIP data,
mPGES-1 is the only target that was identified to be regulated by
the decoy mechanism.
Subcellular Localization of CUGBP1 and
miR-574-5p in A549 Cells
In order to approach the decoy search on a different level, we
wanted to find out exactly where in the cell the interaction
of CUGBP1 and miR-574-5p takes place. Therefore, subcellular
localization of the two binding partners was visualized using
immunofluorescence staining and FISH assay, respectively. miR-
574-5p was detected using a complementary DIG labeled LNA
probe which was visualized with a DIG binding antibody. For
localization of CUGBP1, immunofluorescence staining with a
specific antibody directed against CUGBP1 was performed. DAPI
served as nuclear marker. In fact, it was possible to show that
both, miR-574-5p and CUGBP1 were mainly located within the
nuclei of A549 cells (Figure 5A). While miR-574-5p showed very
weak cytoplasmic signals, CUGBP1 showed a stronger presence
in the cytoplasm, but was still predominantly located in the
nucleus. The cellular localization of both binding partners did not
change upon IL-1β stimulation. Therefore, we concluded that the
decoy mechanism mainly takes place in the nucleus and miR-574-
5p interferes with CUGBP1 functions there, just like it is the case
for the mPGES-1 mRNA regulation.
Bioinformatical 3′UTR Analysis Revealed
That Splicing Pattern of mPGES-1 3′UTR
Is Very Unique
Since both CUGBP1 and miR-574-5p were located in the nucleus,
it was consequential to concentrate on alternative splicing which
is the main function of CUGBP1 within the nucleus. In the
case of mPGES-1, as the decoy target model, CUGBP1 binds
to two binding sites in the mPGES-1 3′UTR and influences
alternative splicing which creates a shorter 3′UTR isoform.
Therefore, we used this as a model and analyzed other potential
decoy candidates concerning this splicing pattern. Sequences of
the 3′UTRs from all 399 proteins which showed an upregulation
in response to 1CUGBP1 in soluble or microsomal fraction of
the proteomics study were downloaded, using ensemble biomart
GRCh38/.p12, version 91, Ensembl variation resources (Hunt
et al., 2018). These 1914 3’UTR sequences were aligned with 42
described CUGBP1 binding motifs [using the online tool Splice
Aid F (Giulietti et al., 2013)]. In a high stringency analysis,
we searched for the exact splicing pattern of mPGES-1, and
found that none of the transcripts represented this exact pattern,
with two 39 and 46 nt binding sites and 1000 nt in between
(Figure 5B, upper panel). Therefore, it was also considered that
the splicing pattern might not have to be identical which is why
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FIGURE 5 | Bioinformatical 3′UTR analysis confirms specificity of mPGES-1-derived splicing pattern. (A) FISH assay and immunofluorescence staining of A549
cells ± IL-1β. miR-574-5p FISH was performed using DIG-labeled miRCURY LNA probes (green). Immunofluorescence staining with specific antibody visualized
subcellular localization of CUGBP1 (red). Nuclei were counterstained with DAPI (blue). Scale bar represents 10 µm in each image. Representative images of three
independent staining experiments are shown. (B) Bioinformatical 3′UTR analysis of upregulated proteins from proteomics study after 1CUGBP1. High
stringency/mPGES-1 splice pattern (upper panel) or low stringency pattern (lower panel) with two or more CUGBP1 binding sites (≥8 nucleotides), with potential
intron (≥100 nucleotides). (C) Summary of the decoy target search. 20 different proteins were analyzed concerning their “decoy regulation pattern” on protein level,
the specific (low stringency) splice pattern in the 3′UTR and binding of CUGBP1 to their mRNA in RIP assays. Nt, nucleotides; FISH, fluorescence in situ
hybridization; RIP, RNA immunoprecipitation. 1, knockdown.
we loosened the criteria in a second low stringency analysis.
We searched for transcripts containing two CUGBP1 binding
sites of at least 8 nt length and with at least 100 nt in between
(Figure 5B, lower panel). As depicted in Table 3, 575 (30%)
of the originally 1914 3′UTRs, contained any CUGBP1 binding
site. Restricting it to binding sites that are 8 nt or longer, only
118 transcripts (6%) were left. Setting the criterion that there
have to be at least two distinct binding sites of at least 8 nt
length, only 33 transcripts were left (1.7%). Finally, including
the criterion that these binding sites have to be at least 100 nt
apart to provide some kind of intron in between, only 11
transcripts (0.6%) fulfilled all the criteria. Those 11 transcripts
belong to nine different genes (Supplementary Table S5):
Superoxide dismutase 2 (SOD2), MAF BZIP Transcription Factor
K (MAFK), CUB domain-containing protein 1 (CDCP1), RNA
Binding Motif Protein 23 (RBM23), SET Domain Containing
Lysine Methyltransferase 7 (SETD7), UBX Domain Protein 2B
(UBXN2B), Complexin 2 (CPLX2), CEP41 and UBE2R2. Of
these, only CEP41 and UBE2R2 depicted the “decoy regulation
pattern.” However, they were not bound by CUGBP1 in the
RIP assay of A549 cells (Figure 4C) and therefore excluded as
novel decoy targets.
DISCUSSION
Since their discovery in 1993 (Wightman et al., 1993), miRs
were generally considered as gene expression repressors. On
post-transcriptional level, miRs specifically bind to 3′UTRs of
their target mRNAs which has a silencing effect by either
mediating translational repression or degradation of the mRNA
(Wienholds and Plasterk, 2005; Croce, 2009). However, over the
last years different studies reported that miRs can also positively
influence gene expression. They can bind to RNA binding
proteins and antagonize their activity which leads to an elevated
gene expression of their target genes (Eiring et al., 2010; Saul
et al., 2016; Saul et al., 2019a,b). The newly discovered decoy of
miR-574-5p and CUGBP1 has a crucial impact on physiological
processes, since it regulates mPGES-1, thereby PGE2 levels and
subsequently lung tumor growth in vivo (Saul et al., 2019a).
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TABLE 3 | Numbers of transcripts in low stringency analysis.








– – – 575
Binding site of ≥ 8 nt – – 118
Binding site of ≥ 8 nt ≥2 binding
sites
– 33
Binding site of ≥ 8 nt ≥2 binding
sites
≥100 nt apart 11
For complete list of transcript IDs see Supplementary Table S5. Nt, nucleotides.
Therefore, it was especially interesting to further characterize this
rather unknown miR function which seems to have a more global
significance than initially assumed.
In a mass spectrometry-based proteomics study, we aimed
to further elucidate global distribution and novel targets
of the decoy mechanism. To this end, we conducted a
proteomics study with manipulated levels of CUGBP1 or miR-
574-5p in A549 lung cancer cells. In this complex study
we separately analyzed proteins from soluble and microsomal
fraction and observed many compartment specific effects.
Especially the R-Smads, SMAD2 and SMAD3 revealed opposite
regulation upon 1CUGBP1 in the two fractions. This supports
the hypothesis that RBPs could allow different translational
efficiencies concerning free and endoplasmic reticulum-bound
ribosomes (Mansfield and Keene, 2009; Reid and Nicchitta,
2012). Moreover, in the two miR conditions (1miR-574-5p and
miR574-5p oe), higher percentages of regulated proteins were
found in the microsomal fraction, compared to the soluble
fraction. This suggests that miR-574-5p is likely to be mainly
localized there and further supports the assumption that the
decoy mechanism occurs in this fraction. In addition, we also
observed that there are more CUGBP1 targets detectable in the
microsomal fraction based on the fact that more proteins were
upregulated than downregulated upon the knockdown. Whereas,
secondary effects were apparently stronger in the soluble fraction,
as 8% of all proteins were decreased upon 1CUGBP1 while
only 2% were increased. This also matches the observation that
CUGBP1 itself is mainly found in the microsomal fraction.
Hence, we focused on the microsomal fraction in further
analyses and identified several new CUGBP1 targets. The NADH-
Ubiquinone Oxidoreductase NDUFS2 was already postulated to
be directly targeted by CUGBP1 (Rattenbacher et al., 2010).
We verified the interaction of CUGBP1 and NDUFS2 via
RIP and could confirm the regulation using Western blot
analysis. This suggests that CUGBP1 influences the respiratory
chain and thereby a major biological process within the cell
(Procaccio et al., 1998). Next, we analyzed the SMAD family.
SMAD2, SMAD3 and SMAD4 were detected in the proteomics
study and expression changes were successfully validated using
Western blot analysis. Interestingly, SMAD7, another SMAD
family member, was not detected in our proteomics study but
nevertheless is described as CUGBP1 target in C2C12, a murine
myoblast cell line (Lee et al., 2010). This gives an indication
that the SMAD family and subsequent pathways could actually
be regulated by CUGBP1 as a regulon. While SMAD2 was
significantly enriched in RIPs, SMAD3 showed no enrichment in
the CUGBP1-IP. This indicates that SMAD2 is indeed bound by
CUGBP1, whereas SMAD3 is not at least under the conditions
investigated here. We can probably speculate that the binding of
SMAD3 mRNA only takes place under certain conditions, since
CUGBP1 is known to bind its targets strictly context specific
(Vlasova and Bohjanen, 2008).
Following, we were interested if these new CUGBP1 targets
were also influenced by the decoy mechanism. Hence, we took
a closer look on their regulation in the microsomal fraction
upon miR-574-5p oe and 1miR-574-5p. It was expected that
targets of the decoy mechanism would be upregulated in response
to an overexpression and downregulated in response to a
knockdown of the miR-574-5p, as it is the case for mPGES-
1. However, microsomal SMAD2 and NDUFS2 did not exhibit
this “decoy regulation pattern” which implies that they are not
affected by the decoy mechanism. In fact, the only protein
depicting the “decoy regulation pattern” in the Western blot
analyses was mPGES-1. However, it should be mentioned that
mPGES-1 did not reveal this pattern in the proteomics data.
We would like to point out that a proteomics study, even if
we have used an established method (Eriksson et al., 2008;
Ochs et al., 2013; Bergqvist et al., 2019; Saul et al., 2019b),
only provides initial indications of which proteins could be
regulated. It does not map the exact expression changes, which
is a common limitation of this approach. It is therefore possible
that mPGES-1 as multi-pass membrane protein is not efficiently,
quantitatively represented by the mass spectrometry due to
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different sample preparation procedures. In contrast to mass
spectrometry samples, protein samples in Western blot analyses
are SDS-treated and boiled. Therefore, it is likely that Western
blot analysis allows for a better quantification in these cases.
This also means, it is possible that there are novel decoy targets
which we did not detect with our proteomics approach. To
ensure the general accuracy of the study, it is crucial to validate
the mass spectrometry data. We addressed this for a selected
amount of proteins and further supported this by additional
validation of the pathway analysis which is in turn based on the
proteomics study.
Interestingly, the decoy mechanism of miR-328 and hnRNP
E2 affects a variety of targets and cellular processes (Saul
et al., 2016, 2019b) while in this case the decoy of miR-574-
5p and CUGBP1 seems to be quite specific for mPGES-1.
Retrospectively, this is consistent with one of our previous studies
in which we firstly demonstrated that miR-574-5p prevents
CUGBP1 from binding to mPGES-1 mRNA. This has a crucial
impact on lung tumor growth in vivo (Saul et al., 2019a) due to
the influence on PGE2 levels and the tumor microenvironment.
However, those pro-tumorigenic effects are completely blocked
with the administration of a selective mPGES-1 inhibitor and
apparently are solely caused by the decoy-mediated mPGES-
1 induction. Therefore, it seems likely that the decoy function
mainly regulates mPGES-1 expression which might be a cell-
type-specific effect.
The hypothesis is further supported by the fact that CUGBP1
and miR-574-5p are mainly located in the nucleus. It is
implied that the role of CUGBP1 as regulator of alternative
splicing is of greater importance here than its function as
translational repressor (Dasgupta and Ladd, 2012). Therefore,
it was assumed that miR-574-5p could solely interfere with this
CUGBP1 function. Thus, we analyzed the splicing pattern that
emerged from the only known decoy target mPGES-1. It has a
specific pattern comprising of two, 39 and 46 nt long CUGBP1
binding sites, separated by a 1000 nt 3′UTR intron (Saul et al.,
2019a). Alternative 3′UTR splicing leads to the generation of a
mPGES-1 isoform with a much higher translational rate. This
can be explained by the fact that inhibitory elements like Alu
elements or canonical miR binding sites within the 3′UTR intron
are removed (Daskalova et al., 2007; Mayr and Bartel, 2009;
Fitzpatrick and Huang, 2012). In a high stringency analysis,
we discovered that this specific splicing pattern is exclusively
found for mPGES-1 and could not be observed for another
potential CUGBP1 target. This can be explained by the fact
that this splice pattern with a 3’UTR Alu element framed by
two CUGBP1 sites is indeed very specific. Thus, we decided
to loosen the criteria and looked for similar patterns in a
second low stringency analysis which resulted in a list of 11
transcripts. Taking into account that we started with nearly
2000 transcripts, this gave us another strong hint that the
decoy mechanism seems to be very specific. In the future it
would be necessary to examine these transcripts more closely
for example in relation to splice variants under inflammatory
or pro-tumorigenic conditions. Further, it should be noted
that we analyzed the 3′UTRs of the transcripts, as we used
mPGES-1 as model for a decoy target. Despite the fact that
CUGBP1 indeed mostly binds to 3′UTRs of target genes, it
is also known to bind to exon-intron boundaries within the
coding sequence (Xia et al., 2017) which we did not include
within this study.
Taken together, in this study we discovered a variety of
potential new canonical targets of CUGBP1 and successfully
verified two of them. By influencing NDUFS2 expression,
CUGBP1 is able to interfere with the respiratory chain and
could have an impact on the mitochondrial complex I (Procaccio
et al., 1998). The newly found interaction with SMAD2 mRNA
opens further possibilities for CUGBP1, since SMAD2 mediates
transforming growth factor β signaling and has a crucial impact
on many signaling cascades (Riggins et al., 1996).
Unexpectedly, we found that the decoy mechanism of
CUGBP1 and miR-574-5p seems to be quite target-specific
in this type of lung cancer cells. Overall, we used several
criteria to identify new targets of the CUGBP1/miR-574-5p
decoy mechanism: First, potential candidates should show a
“decoy regulation pattern” on protein level as we have seen for
mPGES-1. Second, the splice site in the 3′UTR should contain
two CUGBP1 binding sites with a potential intron in between.
Third, binding of CUGBP1 to the respective binding sites occurs.
Interestingly, only mPGES-1 was identified which fulfills all of
these three criteria (Figure 5C). Our data suggest that decoy
mechanisms can lead to the regulation of specific target genes
which is potentially cell-type-specific. Interestingly, in A549
cells, mPGES-1 was identified as the only protein regulated
by the decoy mechanism of CUGBP1 and miR-574-5p. This
explains our previous observation that tumor growth induced by
overexpression of miR-574-5p can be selectively blocked with an
mPGES-1 inhibitor (Saul et al., 2019a). Concerning lung cancer,
mPGES-1 could be a promising target for future lung cancer
therapy in patients overexpressing miR-574-5p.
In light of the observation that not all patients benefit from
a treatment with PGE2-reducing medication (Edelman et al.,
2015; Yokouchi and Kanazawa, 2015), determination of miR-574-
5p levels might be helpful to identify PGE2-dependent tumors.
Hence, the levels of miR-574-5p could serve as stratification
marker to identify subgroups of patients for the treatment with
mPGES-1 inhibitors.
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